Subscribe
Core coverageDFTX

Company profile / DFTX

Definium Therapeutics

Clinaptis stanceConstructive
ConvictionMedium
Ticker
DFTX
Exchange
NASDAQ
Coverage
Standard profile · Research connected
Updated
Oct 3, 2026
Neuroscience / Psychiatry

Late-stage neuropsychiatry company developing DT120 ODT, a single-dose lysergide therapy with positive Phase 3 studies in generalized anxiety disorder and major depressive disorder, alongside additional Phase 3 development in MDD and planned expansion into PTSD.

01 / Clinaptis view

The current read

Constructive, with the clinical replication question substantially de-risked.

  1. PANORAMA reproduced VOYAGE almost exactly where our pre-readout work expected: DT120 100 µg produced a 5.1-point placebo-adjusted HAM-A benefit versus 5.4 points in VOYAGE. Together with positive EMERGE data in major depressive disorder, DT120 has now produced unusually consistent efficacy across three Phase 3 readouts.
  2. PANORAMA also demonstrated statistically significant dose response between 50 µg and 100 µg, strengthening the case that the observed benefit is dose-dependent rather than simply the consequence of receiving a recognizable psychoactive treatment. It does not eliminate functional-unblinding and expectancy questions, but replication has materially reduced the probability that VOYAGE represented an unusually favorable trial realization. The remaining debate therefore moves from whether DT120 works to regulatory interpretation, treatment delivery and commercial adoption.
02 / Consensus gap

Where the market may differ

PANORAMA was clinically successful but produced little incremental rerating, consistent with statistical success already being substantially reflected in valuation.

  1. Our pre-readout work argued that magnitude rather than significance was the relevant variable. PANORAMA’s 5.1-point placebo-adjusted result landed close to the 5.4-point VOYAGE anchor and above the roughly four-point region where we expected commercial differentiation to begin accelerating.
  2. The unresolved question is now commercial rather than efficacy-driven. DT120 requires a prolonged supervised treatment session, operates within a psychedelic regulatory framework and will need sufficient reimbursement and treatment-center throughput to translate unusually large trial effects into a large psychiatry franchise. PANORAMA substantially strengthens the efficacy case; it does not by itself resolve those implementation constraints.
Coverage state
Standard profile · Research connected
What the review turns on
Key variable

Commercial translation after clinical replication. Whether FDA accepts the GAD/MDD package and permits a treatment model sufficiently practical for broad commercial adoption.

Next catalyst

DT120 ODT · FDA pre-NDA meeting · 4Q 2026; NDA submission planned 1H 2027

03 / Pipeline

Key programs

1 asset · 3 programs

AssetIndicationStageNext event
DT120 ODT
Generalized anxiety disorder
Phase 3
FDA pre-NDA meeting expected in 4Q 2026; NDA submission planned in 1H 2027
Major depressive disorder
Phase 3
ASCEND topline expected in 2027 following positive EMERGE results
Post-traumatic stress disorder
Phase 3
HAVEN study initiation expected in 2027
04 / Connected research

Published on DFTX

View full archive
  1. 01

    Definium, Psychedelics & the Price of Replication in Anxiety (GAD)

    Phase 3 PANORAMA in GAD is overwhelmingly likely to succeed statistically. But HAM-A efficacy magnitude matters non-linearly: the value curve steepens around the ~4-point differentiation threshold.

    Read